2026-01-18 - Analysis Report
## AbbVie Inc Stock Report

### Company Overview
AbbVie Inc. is a pharmaceutical company that develops and markets a range of products for various diseases and conditions.

### Comparison with S&P 500

* Return Rate of AbbVie Inc (ABBV) = 175.47%
* Return Rate of S&P 500 (VOO) = 93.36%
* Degree of Divergence (cumulative return on the last day of the data): 175.47% - 93.36% = 82.11%

### Historical Alpha, Beta Analysis

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 50.0% | 16.0% | 46.0% | 1.0 | 162.9B |
| 2017-2019  | 42.0% | 21.6% | 25.0% | 1.1 | 156.5B |
| 2018-2020  | 4.0% | 21.6% | -17.0% | 0.8 | 189.4B |
| 2019-2021  | 61.0% | 20.5% | 18.0% | 0.7 | 239.3B |
| 2020-2022  | 66.0% | 18.5% | 68.0% | 0.6 | 285.6B |
| 2021-2023  | 45.0% | 18.5% | 44.0% | 0.4 | 273.9B |
| 2022-2024  | 37.0% | 18.9% | 18.0% | 0.3 | 314.1B |
| 2023-2025  | 99.0% | 18.9% | 37.0% | 0.3 | 403.8B |

### Recent Stock Price Fluctuations

* Close: $214.35
* Last-market change: -$0.31 (-0.15%)
* 5-day SMA: $218.76
* 20-day SMA: $225.01
* 60-day SMA: $225.80

### Technical Indicators

* Market Risk Indicator (MRI): 0.80 (High Investment Recommended)
* RSI: 34.11
* PPO: -0.56
* Hybrid Signal: Buy (Cash 0%)
* Risk Level: Medium
* Recent relative divergence change: -6.60 (-): worsening
* 7-day Rank change: 0 (0): flat
* 7-day Dynamic Expected Return change: 0.00 (0): flat
* Expected Return (%): 39.60%

### Recent News & Significant Events
- [2026-01-15] AbbVie (ABBV) Stock Dips While Market Gains: Key Facts - Yahoo Finance
- [2026-01-16] AbbVie Call Options Spike 2,599%: Tracking the Big Bet - MarketBeat
- [2026-01-05] AbbVie (ABBV) Stock Falls Amid Market Uptick: What Investors Need to Know - Nasdaq
- [2026-01-14] AbbVie plans to build out its presence in obesity market - Reuters
- [2026-01-14] Assessing AbbVie (ABBV) Valuation After Recent Share Price Weakness - simplywall.st
- [2026-01-12] Fund Update: New $14.2M $ABBV stock position opened by E. Ohman J:or Asset Management AB - Quiver Quantitative

### Analyst Opinions
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.93 (~Buy)
- Opinions: 27
- Target Price (avg/high/low): 245.04 / 289.00 / 184.00

### Comprehensive Analysis (Summary of previous items, including news)
AbbVie Inc. has shown a high return rate compared to the S&P 500, with a degree of divergence of 82.11%. The historical alpha, beta analysis shows a range of CAGR, MDD, Alpha, and Beta values across different time periods. The recent stock price fluctuations indicate a decline in the last market day. The technical indicators show a medium risk level and a worsening relative divergence change. Recent news includes a decline in stock price amid market gains, a spike in call options, and plans to build out presence in the obesity market. Analyst opinions are generally positive with a mean rating of 1.93 and a target price of $245.04.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.